IDEXX Laboratories, Inc. (IDXX)
Automate Your Wheel Strategy on IDXX
With Tiblio's Option Bot, you can configure your own wheel strategy including IDXX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IDXX
- Rev/Share 53.7318
- Book/Share 20.0432
- PB 31.5598
- Debt/Equity 0.0467
- CurrentRatio 1.2307
- ROIC 0.4779
- MktCap 50510757305.0
- FreeCF/Share 13.1983
- PFCF 47.7811
- PE 47.8218
- Debt/Assets 0.0224
- DivYield 0
- ROE 0.6978
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IDXX | Barclays | -- | Overweight | -- | $850 | Dec. 9, 2025 |
| Upgrade | IDXX | Stifel | Hold | Buy | -- | $700 | Oct. 31, 2025 |
| Initiation | IDXX | UBS | -- | Neutral | -- | $720 | Oct. 1, 2025 |
| Reiterated | IDXX | BTIG Research | -- | Buy | $545 | $785 | Aug. 5, 2025 |
| Initiation | IDXX | Jefferies | -- | Buy | -- | $625 | July 1, 2025 |
News
IDEXX Laboratories, Inc. (IDXX) Q1 2025 Earnings Conference Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Emerson - EVP, CFO and Treasurer Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Brandon Vazquez - William Blair Dan Clark - Leerink Partners David Westenberg - Piper Sandler Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' First Quarter 2025 Earnings Conference Call. As a reminder, today's conference is being recorded.
Read More
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago.
Read More
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics
Published: May 01, 2025 by: Reuters
Sentiment: Positive
Animal diagnostics maker IDEXX Laboratories on Thursday raised its annual profit forecast after it beat Wall Street estimates for quarterly profit, as it benefited from customer retention and increased demand for its tests and equipment.
Read More
IDEXX Laboratories Announces First Quarter Results
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. “IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx™, in our North American reference laboratories,” said Jay Mazelsky, President and Chief Executive Officer. “Customers have been askin.
Read More
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Read More
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities.
Read More
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
IDEXX Laboratories to Release 2025 First Quarter Financial Results
Published: April 03, 2025 by: Business Wire
Sentiment: Neutral
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website,.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Should You Retain IDEXX Stock in Your Portfolio for Now?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
Read More
Should You Hold IDEXX Stock in Your Portfolio for Now?
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Positive
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
Read More
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit. Monday, March.
Read More
IDEXX Laboratories And Its Real Value
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Positive
IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years.
Read More
About IDEXX Laboratories, Inc. (IDXX)
- IPO Date 1991-06-21
- Website https://www.idexx.com
- Industry Medical - Diagnostics & Research
- CEO Jonathan J. Mazelsky
- Employees 11000